Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel: prevalence of BRCA1/2 and non-BRCA mutations

Singh, Jaya and Thota, Nishita and Singh, Suhasini and Padhi, Shila and Mohan, Puja and Deshwal, Shivani and Sur, Soumit and Ghosh, Mithua and Agarwal, Amit and Sarin, Ramesh and Ahmed, Rosina and Almel, Sachin and Chakraborti, Basumita and Raina, Vinod and DadiReddy, Praveen K and Smruti, B K and Rajappa, Senthil and Dodagoudar, Chandragouda and Aggarwal, Shyam and Singhal, Manish and Joshi, Ashish and Kumar, Rajeev and Kumar, Ajai and Mishra, Deepak K and Arora, Neeraj and Karaba, Aarati and Sankaran, Satish and Katragadda, Shanmukh and Ghosh, Arunabha and Veeramachaneni, Vamsi and Hariharan, Ramesh and Mannan, Ashraf U (2018) Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel: prevalence of BRCA1/2 and non-BRCA mutations. In: BREAST CANCER RESEARCH AND TREATMENT, 170 (1). pp. 189-196.

PDF Bre_Can_Res_Tra_170-1_189_2018.pdf - Published Version Restricted to Registered users only Download (1MB) | Request a copy

Abstract

Breast and/or ovarian cancers are among the most common cancers in women across the world. In the Indian population, the healthcare burden of breast and/or ovarian cancers has been steadily rising, thus stressing the need for early detection, surveillance, and disease management measures. However, the burden attributable to inherited mutations is not well characterized. We sequenced 1010 unrelated patients and families from across India with an indication of breast and/or ovarian cancers, using the TruSight Cancer panel which includes 14 genes, strongly associated with risk of hereditary breast and/or ovarian cancers. Genetic variations were identified using the StrandNGS software and interpreted using the StrandOmics platform. We were able to detect mutations in 304 (30.1%) cases, of which, 56 mutations were novel. A majority (84.9%) of the mutations were detected in the BRCA1/2 genes as compared to non-BRCA genes (15.1%). When the cases were stratified on the basis of age at diagnosis and family history of cancer, the high rate of 75% of detection of hereditary variants was observed in patients whose age at diagnosis was below 40 years and had first-degree family member(s) affected by breast and/or ovarian cancers. Our findings indicate that in the Indian population, there is a high prevalence of mutations in the high-risk breast cancer genes: BRCA1, BRCA2, TP53, and PALB2. In India, socioeconomic inequality limiting access to treatment is a major factor towards increased cancer burden; therefore, incorporation of a cost-effective and comprehensive multi-gene test will be helpful in ensuring widespread implementation of genetic screening in the clinical practice for hereditary breast and/or ovarian cancers.

Item Type:	Journal Article
Publication:	BREAST CANCER RESEARCH AND TREATMENT
Publisher:	SPRINGER, 233 SPRING ST, NEW YORK, NY 10013 USA
Additional Information:	Copyright of this article belong to SPRINGER, 233 SPRING ST, NEW YORK, NY 10013 USA
Department/Centre:	Division of Electrical Sciences > Computer Science & Automation
Date Deposited:	16 Jul 2018 15:16
Last Modified:	16 Jul 2018 15:16
URI:	http://eprints.iisc.ac.in/id/eprint/60173

Actions (login required)

View Item